Background and importance Hepatocarcinoma (HCC) is the leading cause of mortality in
cirrhotic patients. Sorafenib has been shown to increase survival and is considered firstline …

Background Traditional chemotherapy regimens used in the treatment of non-small cell lung
cancer (NSCLC) have limited efficacy with considerable toxicity. Purpose To analyse the …

Background Natalizumab is indicated in relapsing-remitting multiple sclerosis (RRMS) that
remains highly active despite treatment with interferon B and glatiramer acetate, and in …

Background and importance Eribulin is used, as monotherapy, in the secondline treatment
of locally advanced or metastatic breast cancer (mBC) in patients who have previously …

Background The effectiveness and safety of drugs for the treatment of inflammatory
rheumatic diseases (IRD) are well known. Patients treated with disease modifying …

Background and importance Myelotoxicity is a main concern when treating cancer patients
with chemotherapy. It compromises safety but also the dose intensity received by the patient …

Background The switch from the intravenous (IV) formulation to the subcutaneous (SC)
formulation of abatacept (ABA) had been analysed in clinical trials but there are few data …

Background Biological agents are used to treat rheumatic diseases. Patients are initially
treated at the recommended dose according to the results of clinical trials but there is no …

Background Imatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) available for
chronic myeloid leukaemia (CML) treatment. Newer drugs, with a faster and better response …

Background Proton pump inhibitors (PPIs) are often used inappropriately, without an
indication, or for longer durations than recommended. Deprescribing is defined as the …